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A B S T R A C T
AngII (angiotensin II), ACE (angiotensin I-converting enzyme) and the AT1 receptor (AngII
type 1 receptor) are associated with the inflammatory process and microvascular dysfunction
of AKI (acute kidney injury) induced by renal I/R (ischaemia/reperfusion). However, Ang-(1–7)
[angiotensin-(1–7)], ACE2 (angiotensin I-converting enzyme 2) and the Mas receptor also play a
role in renal disease models. Therefore, in the present study, we have examined the renal profile
of Ang-(1–7), ACE2 and the Mas receptor in renal I/R and compared them with that of AngII,
ACE and the AT1 receptor. Male Wistar rats were submitted to left nephrectomy and ischaemia
(45 min) followed by reperfusion (2 or 4 h) in the right kidney. At 4 h of reperfusion, renal AngII
was increased (P< 0.01) and renal Ang-(1–7) was decreased substantially (P< 0.05), although
plasma levels of both angiotensins were unchanged. In addition, renal I/R decreased the renal
mRNA expression of renin (P< 0.05), AT1 receptors (P< 0.001) and ACE2 (P< 0.05). At 2 and
4 h of reperfusion, renal ACE activity was reduced (P< 0.05). On the other hand, renal expression
of the Mas receptor was greatly increased at 4 h of reperfusion (P< 0.01), which was confirmed by
immunohistochemical and Western blot analysis. In conclusion, increased renal expression of the
Mas receptor associated with changes in the RAS (renin–angiotensin system)-related peptidases
support an important role for the ACE2–Ang-(1–7)–Mas axis in AKI.
INTRODUCTION
AKI (acute kidney injury) is believed to result
from I/R (ischaemia/reperfusion) injuries as occurring
in the course of hypovolaemia, septic shock, renal
transplantation or cardiovascular surgery. I/R leads to
renal vascular dysfunction and subsequent impairment
of renal blood flow, further worsening initial renal
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injury [1,2]. The molecular mechanisms underlying
I/R-induced AKI are not fully understood, but it
has been reported that several causal factors, such as
ATP depletion, production of ROS (reactive oxygen
species), phospholipase activation, neutrophil infiltration
and release of vasoactive peptides, contribute to the
pathogenesis of renal damage [3].
Among the diversity of mediators that take part in
this process, the RAS (renin–angiotensin system) has
progressively assumed an important role. Many studies
have shown that AngII (angiotensin II) contributes to
renal injury in AKI models [4–6]. Kontogiannis and
Burns [4] showed an increase in renal levels ofAngII early
after ischaemia, accompanied by the down-regulation
of cortical angiotensinogen and proximal tubular AT1
receptor (AngII type 1 receptor) mRNAs. This peptide
is released by local and systemic RAS activation and
produces renal vasoconstriction, and sodium and water
retention as well as inflammation and tubular damage
through AT1 receptor activation [7,8].
On the other hand, few studies have investigated the
role of other angiotensins in experimental models of renal
failure. In this regard, Ang-(1–7) [angiotensin-(1–7)] is
particularly interesting, since this peptide is highly ex-
pressed in renal tissue and exerts complex effects in renal
homoeostasis [9–12]. Ang-(1–7) can be formed directly
from AngI (angiotensin I) by neutral-endopepdidase
24.11 and prolyl-endopeptidase or fromAngII via prolyl-
endopeptidase, prolyl-carboxypeptidase [13] and ACE2
(angiotensin I-converting enzyme 2) [14,15]. Ang-(1–7)
binds to a G-protein-coupled receptor, Mas [16], and
plays a counter-regulatory role in the RAS by opposing
the vascular and proliferative effects of AngII [17].
Allred at al. [18] detected increased renal tissue levels
of AngII, whereas renal AngI and Ang-(1–7) remained
unchanged 24 h after ischaemia. However, these authors
also verified an elevation in urinary concentrations of
AngI and Ang-(1–7), and reduced ACE activity and
binding to AT1 receptors [18]. The different pattern of
angiotensin peptides in the urine compared with that
of renal tissue may be indicative of differential regula-
tion of the metabolism of AngI by specific processing
enzymes present within the compartments of the kidney
[18]. More recently, it was shown that ACE inhibition
was able to restore ACE2 activity in the heart [19] and
in the kidney [20], thus ameliorating cardiovascular
and renal damage in subtotal nephrectomized rats. The
presence of Mas mRNA in proximal tubular cells, where
Ang-(1–7) inhibits AngII-induced phosphorylation of
MAPKs (mitogen-activated protein kinases), supports a
renoprotective role for Ang-(1–7) [10]. The intriguing
observation that paediatric patients with end-stage renal
disease present a dramatic increase (25-fold) in plasma
Ang-(1–7) levels [11] indicates further that the ACE2–
Ang-(1–7)–Mas axis may have an hitherto unsuspected
relationship with kidney function. Furthermore, our
group has recently shown that the genetic deletion of
the Mas receptor leads to glomerular hyperfiltration and
also produces structural and molecular changes, which
stimulate renal fibrosis [12].
Therefore it was conceived that the final effects of
the RAS resulted from a balance between two opposite
arms: one, the classical arm, is made up of ACE–AngII–
AT1 receptor and the other, the counter-regulatory arm,
is formed by ACE2–Ang-(1–7)–Mas [17]. The aim of
the present study was to investigate the renal profile of
ACE2–Ang-(1–7)–Mas arm in an experimental model of
AKI and to compare it with the classical arm of the RAS.
MATERIALS AND METHODS
Animals
Male Wistar rats (200–220 g) were housed in a controlled
environment at our local animal facility and had free
access to standard chow and tap water. The study was
approved by the Ethics Committee of our Institution.
I/R injury
Renal I/R was produced according to our protocol
reported previously [21]. Throughout the experiments,
body temperature was kept at 36–38 ◦C by placing the
rats on a heating pad. Rats were anaesthetized with
sodium thiopental (40 mg/kg of body weight) and a
left nephrectomy was performed through a left flank
incision. Renal ischaemia required a right flank incision
and dissection of the right renal pedicle so as to expose the
renal vessels. A thick cotton thread was passed over the
renal vascular pedicle to induce ischaemia. Both ends of
the thread were externalized through the back of the
rat and tied tightly above a length of latex tubing on
the external side of the skin. After the occlusion period
(45 min), the renal pedicle was released cutting the thread
and pulling it out followed by reperfusion, which was
evaluated at 2 (I/R2h) or 4 h (I/R4h). A control group
was used in all experimental protocols. Control animals
were also anaesthetized and submitted to a left
nephrectomy and dissection of the right renal pedicle.
Measurement of MAP (mean arterial
pressure) and urine volume
MAP was measured in the I/R4h group (n= 4) using
a polyethylene catheter placed in the right femoral
artery. MAP was measured continuously during the
45 min of ischaemia and the 4 h of reperfusion. The
pressure signal was monitored by a pressure transducer
(TSD 104A) connected to an amplifier MP100 system
(Biopac Systems) and a computer-measuring program
(Acqknowledge Software). Urine volume was evaluated
in this group of animals.
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Circulating and renal levels of AngII and
Ang-(1–7)
Circulating and renal levels of the main RAS mediators
[AngII and Ang-(1–7)] were determined in the control
(n= 3–8) and I/R4h (n= 5–8) groups. Blood samples
were collected in ice-cooled tubes containing a cocktail
of protease inhibitors (0.01 mM p-hydroxylmercuri-
benzoate, 1.5 mM 1,10-phenanthroline, 0.01 mM PMSF,
0.05 mM pepstatin A and 10 mM EDTA) for measure-
ment of the angiotensins (140 μl per 1 ml of blood).
Blood samples were centrifuged at 2000 g for 20 min at
4 ◦C and the plasma was stored at −20 ◦C. Angiotensin
peptides were alsomeasured in renal tissue. Kidneyswere
homogenized with 0.045 M HCl in ethanol (10 ml/g of
tissue) containing 0.9 mM p-hydroxylmercuribenzoate,
131.5 mM 1,10-phenanthroline, 0.9 mM PMSF, 1.75 mM
pepstatin A, 1.1 mM EDTA and 0.0043% protease-free
BSA and evaporated. After evaporation, the samples were
dissolved in 0.003% TFA (trifluoroacetic acid). Plasma
and tissue samples were extracted using phenyl Bond-
Elut cartridges (Analytichem International). Columns
were activated by sequential washes with 10 ml of 99.9%
methanol/0.1% TFA, 20 ml of 0.1% TFA and 3 ml of
0.1% TFA containing 0.1% BSA. After application of
the samples, the columns were washed with 20 ml of
0.1% TFA and 10 ml of 20% methanol/0.1% TFA, and
the adsorbed peptides were eluted with 3 ml of 99.9%
methanol/0.1% TFA. Using this procedure, recovery of
125I-labelled AngII and Ang-(1–7) was 86.9+− 0.8 and
83.5+− 0.9% respectively. Extracted plasma and renal
tissue samples were resuspended in 650 μl of aqueous
solution containing 0.1% BSA, 0.9% NaCl and 0.003%
acetic acid. AngII and Ang-(1–7) concentrations were
determined by RIA, as described previously [22]. The
protein concentration in the crude homogenates was
determined using the Bradford method [23]. Results for
plasma angiotensins are expressed as pg/ml of plasma and
renal angiotensins are expressed as pg of peptide/mg of
protein.
Renal mRNA encoding components of the
RAS
Renal mRNA levels for renin, angiotensinogen,
AT1 and Mas receptors, ACE, ACE2 and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) were
estimated by quantitative real-time PCR in the control
(n= 5–11), I/R2h (n= 3–7) and I/R4h (n= 3–8)
groups. First, total RNA was extracted from kidneys
using TRIzol® reagent, according to the manufacturer’s
protocol. Reverse transcriptionwas performedusing 1 μg
of total pure RNA, 200 units of reverse transcriptase,
100 mM DTT (dithiothreitol) (1.0 μl), 5× reverse
transcription buffer (2.5 μl), 10 mM dNTPs (1.8 μl),
10000 units RNAsin (0.2 μl) and 50 ng/ml oligo(dT)
(1.0 μl). The profile of temperatures for this reaction was:
25 ◦C for 5 min, 37 ◦C for 60 min, 70 ◦C for 5 min and
4 ◦C for 5 min. Resultant cDNA was used for real-time
PCR as described below. Specific primers were designed
using Primer Express software and synthesized by
Applied Biosystems. Those were (forward and reverse
respectively): renin, 5′-CCACCTTCATCCGCAAGT-
TC-3′ and 5′-TGCGATTGTTATGCCGGTC-3′; angio-
tensinogen, 5′-GACGTGACCCTGAGCAGTCC-3′
and 5′-TGAGTCCCGCTCGTAGATGG-3′; AT1 re-
ceptor, 5′-TCTCAGCATCGATCGCTACCT-3′ and
5′-AGGCGAGACTTCATTGGGTG-3′; Mas recep-
tor, 5′-TGACCATTGAACAGATTGCCA-3′ and 5′-
TGTAGTTTGTGACGGCTGGTG-3′; ACE (5′-CTT-
CACTGACCAAAAGCTGCG-3′ and 5′-CCTAGGG-
TCTGTACGGATCCG-3′; ACE2 (5′-GTGGAGG-
TGGATGGTCTTTCA-3′ and 5′-TTGGTCCACTGT-
TCTCTGGGA-3′; and GAPDH, 5′-ATGTTCCAGT-
ATGACTCCACTCACG-3′ and 5′ GAAGACACCA-
GTAGACTCCACGACA-3′. The AT1 receptor primer
set picks up both AT1a and AT1b receptor subtypes.
Real-time PCR was carried out on an ABI PRISM 7000
sequence detection system (Applied Biosystems) using
SYBR Green PCR Master Mix (Applied Biosystems).
The relative levels of gene expression were determined
by the comparative threshold cycle method, as described
using the manufacturer, in which data for each sample
were normalized to GAPDH.
Renal activities of ACE and ACE2
ACE and ACE2 activities in the rat kidneys of the
control (n= 10–11), I/R2h (n= 6) and I/R4h (n= 7)
groups were determined using quenched fluorigenic
substrates (Abz-peptidyl-EDDnp, where Abz is
o-aminobenzoic acid and EDDnp is 2,4-dinitrophenyl-
ethylenediamine) [24]. Abz-FRK(Dnp)P-OH (specific
to ACE) and Abz-APK(Dnp)-OH (specific to ACE2)
derivatives were determined by continuously measuring
the fluorescence in the cuvette (60 s). The assays were
performed at 37 ◦C in 1 M Tris/HCl buffer (pH 7.0)
containing 50 mM NaCl and 10 μM ZnCl2, in a final
volume of 0.2 ml. The enzymatic activity was monitored
continuously with a Hitachi F-2000 fluorimeter by
measuring fluorescence at an excitation of 320 nm and
an emission of 420 nm. The slope was converted into
μmol of substrate hydrolysed/min on the basis of a
calibration curve obtained after complete hydrolysis of
each peptide. Kidneys were homogenized in the presence
of protease inhibitors (10 μM (2S,3S)-3-(N-{(S)-1-
[N-(4-guanidinobutyl)carbamoyl]3-methylbutyl}carba-
moyl)oxirane-2-carboxylic acid, 1 μM pepstatin A,
1 mM PMSF, 100 μM tosyl-l-lysine chloromethyl
ketone and 100 μM tosyl-l-phenylalanine chloromethyl
ketone). Before starting the reaction by the addition of
10 μM substrate, the tissue homogenates (10 μl≈40 μg)
were pre-incubated for 30 s in the assay buffer at 37 ◦C.
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ACE and ACE2 activities are expressed as m-units/mg
of protein determined using the Bradford method
[23] (where 1 m-unit represents 1 nmol of substrate
hydrolysed/min). The measurements were performed
in duplicate. ACE activity in the presence of the
inhibitor enalapril was determined using 10 μM Abz-
FRK(Dnp)P-OH as substrate. The inhibitor (2.5 μM)
was pre-incubated with samples of kidney tissues for
5 min at 37 ◦C before the addition of the substrate. The
specificity of the assaywas demonstrated by the complete
inhibition of hydrolysis by enalapril. ACE2 activity was
not determined in the presence of the inhibitor.
Western blot analysis of the Mas
receptor
Samples of kidneys (control, n= 3; I/R4h, n= 3) stored
in a lysis buffer [100 mM Tris/HCl (pH 8.0), 1% (v/v)
Triton X-100, 10% (v/v) glycerol, 5 mMEDTA, 200 mM
NaCl, 1 mM DTT, 1 mM PMSF, 2.5 μg/ml leupeptin,
5 μg/ml aprotinin and 1 mM sodium orthovanadate]
were homogenized and centrifuged at 1000 g for 10 min.
Lysates were collected into Eppendorf tubes and aliquots
(approx. 30 μg) were separated by electrophoresis on
a denaturing polyacrylamide [10% (w/v)]/SDS gel
and transferred on to nitrocellulose. Membranes were
blocked overnight, at 4 ◦C, with PBS containing 5%
(w/v) non-fat-dried milk and 0.1% Tween 20, washed
three times with PBS containing 0.1% Tween 20, and
then incubatedwith a specific rabbit polyclonal anti-(Mas
receptor) antibody (1:1000 dilution) and anti-β-actin
antibody (1:3000 dilution) in PBS containing 5% (w/v)
BSA and 0.1% Tween 20. After washing, the membranes
were incubated with HRP (horseradish peroxidase)-
conjugated secondary anti-(rabbit IgG) antibody (1:3000
dilution). Immunoreactive bands were visualized by
using an ECL (enhanced chemiluminescence) detection
system, according to the manufacturer’s instructions
(Amersham Biosciences). Renal Mas receptors were
quantified by using densitometric analysis software
(LabImage), and the values were normalized to the values
of β-actin in the same sample. Changes in protein levels in
the I/R4h group were normalized to those in the control
group, and the Mas receptor/β-actin ratio is expressed in
arbitrary units.
Immunohistochemical analysis of the Mas
receptor
An additional group of rats were anaesthetized with
sodium thiopental (40 mg/kg of body weight) and
perfused with 20 ml of PBS containing the protease
inhibitors PMSF (10 μM), pepstatin A (10 μM), EDTA
(10 μM), 1,10-phenanthroline (10 μM) and sodium
p-hydroxybenzoate (10 μM). Tissue samples from the
kidneys were fixed in Bouin solution, embedded
in paraffin wax and sectioned at 4 μm thickness.
Immunohistochemistry was performed by using the
streptavidin–biotin–peroxidase complex method (Ultra
Vision Large Volume Detection System antipolyvalent,
HRP ready to use; Lab Vision). All samples of kidneys
from the I/R (n= 6) and control (n= 4) groups were
processed at the same time. After exposure to 1% (v/v)
H2O2 in methanol to block endogenous peroxidase,
sections were treated with normal goat serum for
30 min to suppress non-specific binding. The rabbit
anti-(Mas receptor) antibody was diluted 1:1000 in
50 mM PBS and was applied on the slides for 12 h at
4 ◦C. This is a specific polyclonal antibody that cross-
reacts with the rat Mas receptor, but not with other
related angiotensinergic receptors. Sections were treated
with a biotinylated goat anti-(rabbit IgG) antibody for
30 min, at room temperature (22 ◦C), and incubated
with the avidin–biotin–peroxidase complex (Vector) for
60 min. Peroxidase activity was visualized by exposing
the slices for 3 min to 1 mg/ml 3,3′-diaminobenzidine
in PBS containing 0.3% H2O2. The sections were
then counterstained with haematoxylin. In the negative
controls, the primary antibody was pre-adsorbed with
synthetic rat β-endorphin (Peninsula Laboratories).
Additional negative controls consisted of the replacement
of the primary antibody by normal rabbit serum at an
equivalent dilution.
Statistical analysis
Results are shown as means+− S.E.M. Differences
between both I/R groups (I/R2h and I/R4h) and between
each I/R group and controls were compared using
unpaired Student’s t tests.P values<0.05were considered
significant.
RESULTS
MAP and urine volume during I/R
MAP exhibited transient changes during the I/R process.
At baseline (zero time) and at 45 min of ischaemia,
MAP values were 86.0+− 7.6 and 86.5+− 6.0mmHg (n= 4)
respectively. Although not statistically significant, the
peak MAP increase (107.7+− 8.8 mmHg; P> 0.05) was
detected 10 min after the onset of reperfusion, which
returned to basal levels at 2 h of reperfusion (84.0+− 4.0
mmHg). Further changes inMAPwere not detected until
4 h of reperfusion (89.0+− 5.7mmHg). Therewas no urine
elimination during the 4 h of reperfusion.
Circulating and renal levels of AngII and
Ang-(1–7)
Plasma levels of AngII (Figure 1B and Ang-(1–7)
(Figure 1D)were similar in the control and I/R4h groups.
However, the renal levels of AngII in the I/R4h group
were significantly higher than in controls (P< 0.01)
(Figure 1A). In contrast, renal Ang-(1–7) was reduced
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Figure 1 Plasma and renal levels of AngII and Ang-(1–7)
Plasma (B and D) and renal (A and C) angiotensins in the control (n = 3–8) and
I/R4h (n = 5–8) groups were determined by RIA. ∗P < 0.05 and ∗∗P < 0.01
compared with control (determined using an unpaired Student’s t test).
significantly in the I/R4h group when compared with
control group (P< 0.05) (Figure 1C).
Renal mRNA expression of enzymes and
receptors of the RAS
I/R with 2 and 4 h of reperfusion greatly inhibited
renal mRNA expression of renin (P< 0.05, for both
comparisonswith controls) (Figure 2A)without affecting
renal expression of angiotensinogen mRNA (Figure 2B).
ACE mRNA expression was not affected by I/R
(Figure 2C), whereas ACE2mRNA expression remained
unchanged in the I/R2h group, but was significantly
reduced in the I/R4h group (P< 0.05) (Figure 2D).
Concerning receptors, no changes were detected at 2 h
of reperfusion in the mRNA of AT1 (Figure 2E) and Mas
(Figure 2F) receptors in comparison with the control
group. On the other hand, in kidneys from the I/R4h
group, mRNA expression of the AT1 receptor was
decreased (P< 0.001), whereas renal mRNA expression
of theMas receptorwas significantly increased (P< 0.05).
ACE and ACE2 enzyme activities
Despite the absence of a detectable effect onACEmRNA
expression in the I/R2h and I/R4hgroups (Figure 2C), the
renal activity of this enzyme was significantly decreased
in both groups when compared with controls (P< 0.05
for both comparisons; Figure 3A). On the other hand,
renal ACE2 activity was slightly reduced in the I/R2h
group (P< 0.05) and not altered in the I/R4h group in
comparison with the control values (Figure 3B).
Protein expression and
immunohistochemistry of the Mas
receptor in renal tissue
Western blot analysis showed that the anti-(Mas receptor)
antibody detected a band of approx. 33 kDa in kidneys
from the I/R4h group, which was expressed more than
in the control group (Figure 4, upper panel). Renal
expression of β-actin was used as positive control,
without detectable differences between the kidneys from
the control and I/R groups. The Mas receptor/β-actin
ratio is shown in the lower panel of Figure 4. This result
was also corroborated by immunohistochemical analyses
of renal tissue, which showed that the Mas receptor
was present in both cortical and medullar regions of
the kidney (Figure 5). Renal I/R induced an increase
in the Mas receptor density compared with the control
group. Figure 5(A) (×20 magnification) and Figure 5(C)
(×60 magnification) show representative slices of the
renal cortex, and Figure 5(E) is a representative slice
of renal medulla from kidneys from the control group.
It was possible to observe the Mas receptor (brown
spots corresponding to the antibody binding to the Mas
receptor) predominantly localized in the proximal and
distal tubules, but also in the glomerulus (Figures 5A
and 5C) and in the thick ascending limb of the loop of
Henle (Figure 5E). Slices of cortex (Figures 5B and 5D)
andmedulla (Figure 5F) from kidneys after I/R show that
glomerulus, proximal and distal tubules and thick ascend-
ing limb of the loop ofHenlewere stainedmore intensely,
showing high concentrations of the Mas receptor.
DISCUSSION
It is known that the classical RAS axis, formed by
ACE–AngII–AT1 receptor, participates in the process
of AKI [4–6]. However, the results of the present study
provide evidence for a pathophysiological role for the
counter-regulatory RAS axis, consisting of ACE2–
Ang-(1–7)–Mas, in an experimental model of renal I/R.
Although renal levels of AngII were elevated, Ang-(1–7)
was reduced in renal tissue at 4 h of reperfusion. In
addition, the renal expression of ACE2 was also reduced,
but its activity remained unchanged. On the other
hand, renal expression of ACE was unchanged, while
its activity was decreased. Regarding receptors, at 4 h
of reperfusion, the Mas receptor was highly expressed
in renal tissue, whereas renal expression of the AT1
receptor was reduced. These findings clearly show the
complexity of the interactions between both arms of
the RAS axis in AKI.
Our group has previously characterized this AKI
model by showing significant renal function impairment
and an increased inflammatory response [21]. In
addition, changes in vascular permeability and neutrophil
accumulation were also observed [21]. Accordingly,
previous studies have shown that AngII contributes
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Figure 2 Renal mRNA encoding components of the RAS
Renal mRNA of renin (A), angiotensinogen (B), ACE (C), ACE2 (D), the AT1 receptor (E) and the Mas receptor (F) in the control (n = 5–11), I/R2h (n = 3–7) and
I/R4h (n = 3–8) groups were determined by quantitative real-time PCR. ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001 compared with control (determined using an
unpaired Student’s t test).
Figure 3 Activities of renal angiotensin-forming enzymes
Renal activity of ACE (A) and ACE2 (B) in the control (n = 10–11), I/R2h (n = 6) and I/R4h (n = 7) groups were determined using quenched fluorogenic substrates.
∗P < 0.05 compared with control (as determined using an unpaired Student’s t test). mU, m-unit.
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Figure 4 Western blot analysis of the renal Mas receptor
Upper panel, a representative immunoblot with the bands representing the renal
Mas protein in the control (lanes 1–3) and I/R4h (lanes 4–6) groups. Lower
panel, the Mas receptor/β-actin ratio determined by densitometry. ∗∗P < 0.01
compared with control (determined using an unpaired Student’s t test).
to renal damage in AKI models [4–6]. On the other
hand, Ang-(1–7) also exerts complex renal actions at the
glomerular and tubular levels, which may vary according
to its concentration in renal tissue and to interactions
with other renal mediators [9,17,18]. In this regard,
Ang-(1–7) appears to be able to modulate renal plasma
flow, glomerular filtration rate and fluid reabsorption
[9,12,25,26]. In addition, Ang-(1–7) acts as an antifibrotic
mediator in cardiovascular and hepatic tissues [27,28],
but also in the kidney, as shown by the pro-fibrotic
phenotype of mice with genetic deletion of the Mas
receptor [12]. Therefore the predominance of AngII
rather thanAng-(1–7) in renal tissue probably contributes
to renal injury in our AKI model.
Members of the RAS cascade were also significantly
affected in our experimental model. Renal expression of
the precursor of this system, angiotensinogen, remained
unchanged, but renin is locally inhibited. There are few
studies addressing the levels of angiotensinogen in I/R
models [4,29]. Kontogianis and Burns [4] showed a
decrease in renal angiotensinogen mRNA at later stages
of the I/R process. Concerning renin, in one study [6],
a significant inhibition of renal renin mRNA at 5 weeks
after ischaemia was observed, but others have reported an
increase in activity at 24 h post-surgery [18,30]. Maybe
Figure 5 Renal immunohistochemistry of the Mas receptor
Representative sections of the renal cortex (A–D) and renal medulla (E and F) from the control group (A, C and E) and the I/R4h group (B, D and F). Results are
representative of n = 4 and n = 6 in the control and I/R4h groups respectively. Kidneys from the I/R4h group were stained more intensely, indicating a higher
density of the Mas receptor in both the renal cortex and medulla. (A and B), ×20 magnification; (C and D), ×60 magnification; (E and F), ×40 magnification.
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other enzymes, besides renin, could be involved in RAS
metabolism in experimental AKI.
The current view of the RAS suggests that the
balance between ACEs is critical to the regulation of
the system in different organs [31,32]. Although the
major product of ACE is AngII, ACE2 is the main
enzyme responsible for the conversion of AngII into
Ang-(1–7) at least in renal tissue [25]. In our present
study, renal ACE mRNA expression was unchanged,
but ACE activity was reduced. On the other hand,
renal ACE2 mRNA expression was reduced, whereas
the activity of this enzyme remained unaltered. Despite
the reduced renal expression of ACE2, the activity of
this enzyme was higher than ACE activity. The balance
between ACEs has been reported in different organs and
experimental conditions.Myocardial infarction increased
both ACE and ACE2 mRNA levels in rats and
humans [31]. In addition, ACE2 gene expression is up-
regulated in the failing human heart [32]. Alternatively,
Ishiyama et al. [33] observed that ACE2 expression
in Lewis normotensive rats increased only after AT1
receptor blockade. Concerning renal tissue, Lely et
al. [34] showed neoexpression of ACE2 in glomerular
and peritubular capillary endothelium in patients with
diverse nephropathies and in transplanted kidneys. In
contrast, Tikellis et al. [35] detected a 50% decrease in
ACE2 mRNA expression in diabetic renal tubules. More
recently, Velkoska et al. [20] reported that ACE2 activity
is reduced in subtotal nephrectomized rats and that ACE
inhibition produced beneficial effects in association with
increased renal ACE2 activity. These divergent results
further suggest that the regulation of ACE and ACE2
levels and activities is very complex and depends on the
experimental condition [36,37]. In ourAKImodel, ACE2
activity in the I/R4h rats was not significantly reduced
as occurred with ACE activity (approx. 45% reduction)
in comparison with controls. This differential reduction
in enzyme activity could be a compensatory pathway
to increase Ang-(1–7) synthesis, which may therefore
represent a more general counter-regulatory response to
the multiple deleterious effects of increased local AngII
production. This possibility was also addressed by Su
and co-workers [10], who suggested that the synthesis
of Ang-(1–7) in the proximal tubule could represent an
endogenous pathway that limits the ability of local AngII
to stimulate cell growth responses, and by the finding that
the genetic deletion of the Mas receptor resulted in renal
dysfunction and in a pro-fibrotic phenotype [12].
The differential expression of angiotensin receptors
further supports the complex relationship between the
ACE–AngII–AT1 receptor and ACE2–Ang-(1–7)–Mas
axes. Although quantification of the results (renal content
of angiotensins, Mas receptor mRNA and Mas receptor
protein) in the present study was made in kidney
slices containing renal cortex and medulla, qualitative
immunohistochemical analysis showed an increase in
expression of Mas protein in proximal tubular cells and
glomeruli (cortex) and in the thick ascending limb of the
loop of Henle (medulla). In contrast, mRNA expression
of the AT1 receptor was reduced in the kidneys from
the I/R4h group. Other studies have also shown the
inhibition of the AT1 receptor in an I/R model [4]. In this
regard, Ang-(1–7) and the Mas receptor could interfere
with AT1 receptor expression. Indeed, at physiological
concentrations, Ang-(1–7) is an endogenous modulator
of AT1-receptor-mediated AngII responses [29]. Ang-
(1–7) antagonized the AngII-induced activation of PKC
(protein kinase C) and MAPK [ERK1/2 (extracellular-
signal-regulated protein kinase 1/2)] in vascular smooth
muscle cells [38] and attenuated the AngII-induced
ROS (reactive oxygen species) generation, c-Src and
ERK1/2 activation in CHO (Chinese-hamster ovary)
cells transfected with the Mas receptor and in human
aortic endothelial cells [39]. AngII-induced ERK1/2
phosphorylation was also inhibited by Ang-(1–7) in rat
cardiomyocytes [40] and proximal tubular cells [10]. In
addition, Kostenis et al. [41] have demonstrated that
the Mas receptor can hetero-oligomerize with the AT1
receptor and, by so doing, inhibit the actions of AngII.
Furthermore, Mas-receptor-knockout mice also have an
increased expression of AT1 receptor mRNA in renal
tissue [12], corroborating the hypothesis that the Mas
receptor acts as an antagonist of the AT1 receptor [41].
In conclusion, tissues may regulate their local
angiotensin concentrations by varying the number of
renin receptors, ACE and ACE2 levels and activities,
the amount of metabolizing enzymes and angiotensin
receptor density and subtypes [17,25]. Renal ischaemia
appears to change or to modulate the profile of
components of the RAS. Despite the amount of work still
needed to fully understand the functional implications
of the novel concept of the RAS, evidence obtained so
far indicates that the counter-regulatory axis of the RAS
was recruited to balance the actions of the classical RAS
axis at early stages of the AKI process. Therefore we
believe that therapeutic measures leading to activation of
the ACE2–Ang-(1–7)–Mas axis are a promising strategy
for the development of new treatments for AKI.
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